Screening of ferritin light polypeptide 460-461InsA mutation in Parkinson's disease patients in North America

Neuroscience Letters

Volumn 335, Issue 2, 2002, Pages 144-146

  Chen, Rong ^a   Langston, J William ^a   Chan, Piu ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

Ferritin light polypeptide; Iron metabolism; Mutation screening; Parkinson's disease

Indexed keywords

ADULT; AGED; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DNA POLYMORPHISM; EXTRAPYRAMIDAL SYNDROME; FAMILY; FEMALE; FERRITIN LIGHT POLYPEPTIDE GENE; GENE; GENE MUTATION; GENETIC DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PARKINSON DISEASE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; FERRITINS; GENETIC SCREENING; HUMANS; LINKAGE (GENETICS); MALE; MUTAGENESIS, INSERTIONAL; NORTH AMERICA; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0037176195     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(02)01185-0     Document Type: Article

References (20)

1. Curtis A.R., Fey C., Morris C.M., Bindoff L.A., Ince P.G., Chinnery P.F., Coulthard A., Jackson M.J., Jackson A.P., McHale D.P., Hay D., Barker W.A., Markham A.F., Bates D., Curtis A., Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28:2001;350-354.
2. Dexter D.T., Wells F.R., Agid F., Lees A.J., Jenner P., Marsden C.D. Increased nigral iron content in postmortem parkinsonian brain. Lancet. 2:1987;1219-1220.
3. Dexter D.T., Carayon A., Vidailhet M., Ruberg M., Agid F., Agid Y., Lees A.J., Wells F.R., Jenner P., Marsden C.D. Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55:1990;16-20.
4. Dexter D.T., Jenner P., Schapira A.H., Marsden C.D. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia: The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 32:1992;S94-100.
5. Dexter D.T., Sian J., Rose S., Hindmarsh J.G., Mann V.M., Cooper J.M., Wells F.R., Danial S.E., Lees A.J., Schapira A.H., Jenner P., Marsden C.D. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35:1994;38-44.
6. Double K.L., Riederer P.F., Gerlach M. Role of iron in 6-hydroxydopamine neurotoxicity. Adv. Neurol. 80:1999;287-296.
7. Double K.L., Gerlach M., Youdim M.B., Riederer P. Impaired iron homeostasis in Parkinson's disease. J. Neural. Transm. Suppl. 60:2000;37-58.
8. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807.
9. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., Richardson R.J. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology. 48:1997;650-658.
10. Graham J.M., Paley M.N., Grunewald R.A., Hoggard N., Griffiths P.D. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain. 123(Pt 12):2000;2423-2431.
11. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol. Scand. Suppl. 146:1993;6-13.
12. Langston J.W., Widner H., Goetz C.G., Brooks D., Fahn S., Freeman T., Watts R. Core assessment program for intracerebral transplantations (CAPIT). Mov. Disord. 7:1992;2-13.
13. LaVaute T., Smith S., Cooperman S., Iwai K., Land W., Meyron-Holtz E., Drake S.K., Miller G., Abu-Asab M., Tsokos M., Switzer R., Grinberg A., Love P., Tresser N., Rouault T.A. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27:2001;209-214.
14. Logroscino G., Marder K., Graziano J., Freyer G., Slavkovich V., LoIacono N., Cote L., Mayeux R. Altered systemic iron metabolism in Parkinson's disease. Neurology. 49:1997;714-717.
15. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., Schapira A.H. Complex I iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36:1994;876-881.
16. Mochizuki H., Imai H., Endo K., Yokomizo K., Murata Y., Hattori N., Mizuno Y. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci. Lett. 168:1994;251-253.
17. Norfray J.F., Chiaradonna N.L., Heiser W.J., Song S.H., Manyam B.V., Devleschoward A.B., Eastwood L.M. Brain iron in patients with Parkinson disease: MR visualization using gradient modification. Am. J. Neuroradiol. 9:1988;237-240.
18. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
19. Yoshida K., Furihata K., Takeda S., Nakamura A., Yamamoto K., Morita H., Hiyamuta S., Ikeda S., Shimizu N., Yanagisawa N. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat. Genet. 9:1995;267-272.
20. Zayed J., Ducic S., Campanella G., Panisset J.C., Andre P., Masson H., Roy M. Environmental factors in the etiology of Parkinson's disease. Can. J. Neurol. Sci. 17:1990;286-291.